Please login to the form below

Not currently logged in


This page shows the latest glaucoma news and features for those working in and with pharma, biotech and healthcare.

Astellas makes another gene therapy play with Juventas deal

Astellas makes another gene therapy play with Juventas deal

The option deal comes just a few weeks after Astellas acquired UK ocular gene therapy company Quethera for $109m, adding a potential treatment for glaucoma called QTA020V which is in in

Latest news

More from news
Approximately 3 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    For example, Allergan has acquired ForSight Visions, a company that has developed a peri-ocular device that allows extended release of a drug to reduce intra-ocular pressure in glaucoma patients. ... 105. ForSight Visions. Allergan. Company acquisition.

  • Digital Business Models Digital Business Models

    For example, a pressure sensor in a smart contact lens monitors and controls intra-ocular pressure levels as well as identifies early cases of glaucoma.

  • Pharma deals in September 2015 Pharma deals in September 2015

    Acquisition - product. 445. Aquesys. Allergan. Implantable shunt for glaucoma. Acquisition - company.

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    R&D focus is on discovering new treatments for conditions including age-related macular degeneration (AMD), eye allergies, infections, inflammation, dry eye, glaucoma, cataract and refractive errors.

  • Opening the public's eyes

    Journalists from eight European countries attended, with 22 articles published during World Glaucoma Week. ... Accurate diagnosis of glaucoma can improve the likelihood of successful treatment and prevent blindness.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Schneider has 16 years’ experience of clinical drug development and prior to her new role, she most recently served Allergan as its vice president and therapeutic head of retina and glaucoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...